Therapeutic approaches for non-alcoholic steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have been reported as a novel worldwide epidemic, very often associated with obesity, metabolic syndrome, and type 2 diabetes. Both conditions have also been shown to be associated with a number of endocrine pathologi...
Main Authors: | Luc F. Van Gaal, Jonathan Mertens, Sven Francque, Christophe De Block |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-09-01
|
Series: | Therapeutic Advances in Endocrinology and Metabolism |
Online Access: | https://doi.org/10.1177/20420188211034300 |
Similar Items
-
Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
by: Sven Francque, et al.
Published: (2013-10-01) -
Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
by: Wim Verlinden, et al.
Published: (2020-11-01) -
Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
by: Carmelo Luci, et al.
Published: (2020-12-01) -
Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
by: Shinji Takai, et al.
Published: (2020-10-01) -
Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
by: Shinji Takai, et al.
Published: (2018-02-01)